HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.6%

Neg 0% Neu 89.6% Pos 0%

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.